## ABBV: AbbVie Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.41 indicates fundamental undervaluation. Quality metrics strong (ROE 138%). Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($219.18)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. AbbVie Inc. stock outperforms competitors on strong trading day**
- Source: MarketWatch | 20251203T163100 | Bullish | Relevance: 100%
- Shares of AbbVie Inc. (ABBV) rose 2.62% to $230.24 on Wednesday, outperforming the broader market. This gain broke a two-day losing streak for the stock, as the S&P 500 Index and Dow Jones Industrial Average also saw increases.

**2. AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers**
- Source: Investing News Network | 20251203T002136 | Bullish | Relevance: 100%
- AbbVie (NYSE: ABBV) announced it will present new data at the 2025 American Society of Hematology (ASH) Congress, highlighting advancements in treating multiple blood cancers with novel therapeutic modalities. Key presentations will feature investigational compounds etentamig and PVEK, alongside approved therapies EPKINLY® and VENCLEXTA®, demonstrating promising efficacy and safety profiles across various hematologic malignancies. The data reinforces AbbVie's leadership in oncology and commitment to improving care standards for patients with difficult-to-treat blood cancers.

**3. AbbVie (ABBV) Stock on December 2, 2025: Dividend Hike, Cancer Pipeline Momentum and 2026 Outlook**
- Source: ts2.tech | 20251202T211913 | Bullish | Relevance: 100%
- This article provides an in-depth analysis of AbbVie (ABBV) stock as of December 2, 2025, highlighting its recent dividend hike, momentum in its oncology and migraine pipelines, and positive outlook for 2026. It covers the stock's price, valuation, dividend profile, recent Q3 2025 earnings, strategic mergers and acquisitions, and Wall Street analyst ratings, while also addressing key risks for investors.

**4. AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73**
- Source: Simply Wall Street | 20251202T193951 | Neutral | Relevance: 100%
- AbbVie (NYSE:ABBV) announced an increase in its dividend to $1.73 per share, payable on February 17th, with a yield of 3.1%. While cash flow covers the dividend despite recent profit declines, the company's dividend growth potential is considered shaky due to a 22% annual EPS decline over the past five years, though earnings are predicted to rise in the next year. Investors should be aware of potential risks despite the consistent dividend policy.

**5. AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73**
- Source: Simply Wall Street | 20251202T191409 | Somewhat-Bullish | Relevance: 100%
- AbbVie Inc. (NYSE:ABBV) has announced an increase in its dividend to $1.73, payable on February 17th, with the dividend yield approximately matching the industry average at 3.1%. While future dividend projections appear well-covered by cash flow despite past profit deficits, the company's EPS has declined by 22% per year over the last five years, raising concerns about long-term dividend sustainability even with predicted earnings growth in the next year. Investors should consider these factors alongside the company's solid track record of dividend growth.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 3, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-07 | UBS | $220 | $195 | +13% |
| 2025-11-05 | Piper Sandler | $289 | $284 | +2% |
| 2025-11-03 | Citigroup | $235 | $240 | -2% |
| 2025-11-03 | JP Morgan | $260 | $250 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-07 | UBS | main | Neutral |
| 2025-11-05 | Piper Sandler | reit | Overweight |
| 2025-11-03 | Citigroup | main | Neutral |
| 2025-11-03 | JP Morgan | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($0.06M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.1% (+0.2%)
- Blackrock Inc.: 8.3% (-1.0%)
- JPMORGAN CHASE & CO: 6.4% (+97.6%)
- State Street Corpora: 4.5% (-0.2%)
- Morgan Stanley: 2.4% (-0.1%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 3 raises (avg +6%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.41 indicates undervaluation relative to growth. Forward P/E 16.2x attractive for 34% earnings growth. Quality metrics strong (ROE 138%). Balance sheet: $6.5B free cash flow. Analyst sentiment positive (3 raises, avg +6%). Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $406.5B |
| Beta | 0.35 |
| 52W Range | $164.39 - $244.81 |
| Short Interest | 1.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.41 |
| Forward P/E | 16.2 |
| Current P/E | 21.6 |
| YoY Growth | 33.9% |
| EPS Direction | FALLING |

### Technicals

MRS_20 weakening modestly (-0.8% over 5 days). Below STRENGTH zone by 4.9pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.9%) - potential reversal signal. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 53. OFD pattern: +FTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.94% (CS: 42) | Neutral |
| RSI_14 | 53.4 | Neutral |
| MACD Histogram | -0.48 | Bearish |
| vs SMA20 | 1.010x | Above |
| vs SMA50 | 1.011x | Above |
| vs SMA200 | 1.127x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $230.24
- **Stop Loss:** $219.18 (4.8% risk)
- **Target:** $252.36 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 85
- **Position Value:** $19,570.40
- **Portfolio %:** 19.57%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-06 (Est: $3.35)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.78 | $1.86 | +4.2% |
| 2025Q2 | $2.91 | $2.97 | +2.1% |
| 2025Q1 | $2.40 | $2.46 | +2.6% |
| 2024Q4 | $2.12 | $2.16 | +1.9% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*